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Abstract
Background: There are several reasons that someone might be diagnosed with more than one
primary cancer. The aim of this analysis was to determine combinations of cancer types that occur
more often than expected. The expected values in previous analyses are based on age-and-gender-
adjusted risks in the population. However, if cancer in people with multiple primaries is somehow
different than cancer in people with a single primary, then the expected numbers should not be
based on all diagnoses in the population.
Methods: In people with two or more cancer types, the probability that a specific type is diagnosed
was determined as the number of diagnoses for that cancer type divided by the total number of
cancer diagnoses. If two types of cancer occur independently of one another, then the probability
that someone will develop both cancers by chance is the product of the individual probabilities for
each type. The expected number of people with both cancers is the number of people at risk
multiplied by the separate probabilities for each cancer. We performed the analysis on records of
cancer diagnoses in British Columbia, Canada between 1970 and 2004.
Results: There were 28,159 people with records of multiple primary cancers between 1970 and
2004, including 1,492 people with between three and seven diagnoses. Among both men and
women, the combinations of esophageal cancer with melanoma, and kidney cancer with oral
cancer, are observed more than twice as often as expected.
Conclusion: Our analysis suggests there are several pairs of primary cancers that might be related
by a shared etiological factor. We think that our method is more appropriate than others when
multiple diagnoses of primary cancer are unlikely to be the result of therapeutic or diagnostic
procedures.
Background
There are several reasons that someone might be diag-
nosed with cancer at more than one anatomic site. First, a
new cancer might be caused by the therapy for a previous
Published: 08 November 2006
Emerging Themes in Epidemiology 2006, 3:17 doi:10.1186/1742-7622-3-17
Received: 16 March 2006
Accepted: 08 November 2006
This article is available from: http://www.ete-online.com/content/3/1/17
© 2006 Bajdik et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Emerging Themes in Epidemiology 2006, 3:17 http://www.ete-online.com/content/3/1/17
Page 2 of 6
(page number not for citation purposes)
cancer. The risk of breast cancer is significantly increased
among women who were treated for Hodgkin Disease
with radiation [1]. Second, cancer might occur at multiple
sites because a factor is associated with cancer at each site.
Germline mutations in mismatch repair genes can pro-
duce susceptibility to cancers of the colorectum, ovary,
stomach, small bowel, upper uroepithelial tract, hepato-
biliary tract and brain [2]. Likewise, cigarette smoking
affects the risk of several cancer types. Third, a different
cancer type might be diagnosed because of diagnostic or
surveillance procedures associated with a previous cancer.
Cancers of the prostate are more likely to be diagnosed in
men with bladder cancer because both can be diagnosed
during the physical examination performed by a urolo-
gist. Finally, many people are diagnosed with more than
one cancer because of chance. More than a third of Cana-
dians is diagnosed with cancer during their lifetime [3].
Whatever the explanation, the non-chance incidence of
multiple cancers in someone implies the diseases are
related. Several previous analyses have compared the
observed and expected incidence of all cancer types in
people with multiple diagnoses [1,4-8]. The expected val-
ues in these analyses are based on age-and-gender-
adjusted risks in the population. The time between diag-
noses is usually considered an indication of the second
cancer's cause. However, if cancer in people with multiple
primaries is somehow different than cancer in people with
a single primary, then the expected numbers should not
be based on the risks among people with a single primary.
A recent report recommended the design of new epidemi-
ological methods to study second primary cancers [9]. We
compare the observed and expected values of second pri-
mary cancers in British Columbia (BC), Canada, where
the expected number for each cancer type ignores a per-
son's age at diagnosis, and the time between cancer diag-
noses. We think that our method is appropriate if an
underlying risk factor, either genetic or environmental, is
responsible for both cancer types.
The aim of this analysis was to determine what types of
cancer occur more often than expected in people who are
diagnosed with multiple primary cancers. We did this
using records of cancer diagnoses between 1970 and 2004
from the BC Cancer Registry (BCCR). Permission to report
the analysis was received from the Research Ethics Board
at the University of British Columbia.
Analysis
The data comprised records of all people who were diag-
nosed with more than one primary invasive cancer in BC
between 1970 and 2004. Primary cancer refers to dysplas-
tic growth that is not the metastases of another tumor.
Invasive cancer is disease that is neither benign nor in situ.
The data were obtained from the BCCR, a population-
based registry that includes medical records for all cancer
that have occurred in the population since 1962. The
BCCR has a high level of data completeness based on
standard international measures of cancer registration
[10]. The diagnoses were classified as distinct cancer types
according to the anatomic sites reported by the National
Cancer Institute of Canada [3] and are defined using the
International Classification of Disease for Oncology
(ICD-O [11]). We excluded patient records that showed
multiple diagnoses of the same cancer type because we
were concerned these diagnoses might refer to the recur-
rence of previous disease.
A two-way table was created in which both the rows and
columns represent cancer types. A table cell is the
observed number of people (O) in the dataset with a diag-
nosis of both the types specified by the row and column.
People who were diagnosed with more than two cancer
types contributed to each relevant pair-wise tally. For
example, someone diagnosed with each of lung, colorec-
tal and stomach cancer would contribute 1 to the pairwise
observations of lung-and-colorectal cancer, lung-and-
stomach cancer, and colorectal-and-stomach cancer.
In people with two or more cancer types, the probability
that a specific type is diagnosed can be determined as the
number of diagnoses for that cancer type divided by the
total number of cancer diagnoses. If two types of cancer
occur independently, then the probability that someone
will develop both cancers by chance is the product of the
individual probabilities for each type. The expected
number of people with both cancers (E) is the number of
people at risk multiplied by the separate probabilities for
each cancer. Explicitly, if there are N diagnoses of cancer
in total, OA diagnoses of cancer type A and OB diagnoses
of cancer type B, then
EAB = (OA/N) × (OB/N) × N   (1)
where EAB is the expected number of people who will be
diagnosed with both cancer types A and B. The observed-
expected ratio (O/E) is a measure of the cancer types' relat-
edness in the population. For people with more than one
type of cancer, an O/E value of 1 indicates that a pair of
cancer types was diagnosed as often as would be expected
given the likelihood of being diagnosed with each cancer
type. An O/E value less than 1 indicates a pair is less likely
to be observed than all multiple primary records suggest,
and an O/E value greater than 1 indicates a pair of cancer
types occurs more frequently than would be expected. An
approximate 95% confidence interval (95% CI) is O/E ±
(1.96/√E), and we describe the relatedness of a cancer pair
as "significant" when this confidence interval excludes 1.Emerging Themes in Epidemiology 2006, 3:17 http://www.ete-online.com/content/3/1/17
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Results
There were 28,159 people with records of multiple pri-
mary cancers in the BCCR between 1970 and 2004,
including 1,492 people with between three and seven
diagnoses. A cross-tabulation of the observed values for
each pair of cancer types is shown in Figure 1. The most
common pairs were prostate-colorectal, prostate-lung and
prostate-bladder. These pairs were observed in males only,
and reflect that each of the individual cancer types is rela-
tively common. The next-most common pair was breast-
colorectal and almost all paired diagnoses were observed
in women. As in the three most-common pairs, the fourth
pair reflects that each of the individual cancer types is rel-
atively common in BC women. Together, the four most-
common pairs reflect that cancer in BC is more common
among men than among women. Approximately 6% of
diagnoses in Table 1 were classified as "other" cancer and
occurred at unspecified, ill-defined and unknown sites.
For men and women separately, Table 2 shows the com-
binations of cancer types for which there were at least two
people diagnosed with both cancers and there is more
than twice as many observed cases as expected. Among
women, only the combination of cervical with oral cancer
has an observed O/E ratio for which the 95% confidence
interval excludes 1. Among men, several combinations of
cancer types have O/E ratios for which the 95% confi-
dence interval excludes 1. Among both men and women,
the combination of esophageal cancer with melanoma,
and kidney cancer with oral cancer, are observed more
than twice as often as expected. However, for neither com-
bination in women does the ratio's 95% confidence inter-
val exclude 1.
Discussion
Our analysis suggests that several pairs of primary cancers
might be related by a shared etiological factor. Someone's
multiple primary cancer diagnoses instead might result
from disease treatment or increased disease surveillance,
but the lack of a specific temporal interval (or even order)
between diagnoses inclines us to believe otherwise. The
method of analysis that we propose in this paper is more
appropriate than others when a shared etiologic factor is
likely. An example of potential insights that are offered by
The number of cancer diagnoses in British Columbia among people with diagnoses of two or more types of primary cancer  between 1970 and 2004 Figure 1
The number of cancer diagnoses in British Columbia among people with diagnoses of two or more types of primary cancer 
between 1970 and 2004. To ensure patient confidentiality in our population, all tables entries ≤5 have been replaced by an 
asterisk (i.e., *). Note that row totals (not shown) are the same as the corresponding column totals.Emerging Themes in Epidemiology 2006, 3:17 http://www.ete-online.com/content/3/1/17
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the method is provided by multiple cancer diagnoses
where one diagnosis is melanoma. Previous reports sug-
gest that melanoma diagnoses occur more often than
expected after diagnoses of lip cancer, prostate cancer,
ovarian cancer, lymphoma and leukemia [7,12,13]. In
addition, previous reports suggest that oropharyngeal
cancer, brain cancer, prostate cancer, kidney cancer, lym-
phoma and leukemia are significantly more common
than expected in patients with a prior diagnosis of
melanoma [7,13-18]. Our analyses indicate that, in BC
men, a diagnosis of melanoma either follows or preceeds
a diagnosis of bladder, esophageal, laryngeal or lung can-
cer – and this happens significantly more often than
expected. It is quite possible that factors, genetic or other-
wise, affecting a man's risk of melanoma also affects his
risk of bladder, esophageal, laryngeal and lung cancer.
Likewise, risk factors for the other cancers might affect a
man's melanoma risk.
We recently developed the computer software CGMIM
[19] that reviews Online Mendelian Inheritance in Man
(OMIM [20]) to identify genetically-related cancers [21].
OMIM is a computerized database of information about
genes and heritable traits in human populations. CGMIM
creates a matrix of observed/expected values as in Figure 1,
but the values are determined by text-mining the gene
descriptions in OMIM. Results are posted on the CGMIM
website [19] monthly and suggest cancer types that are
related genetically. Current CGMIM results (website
accessed Sept 5, 2006) suggest that cancer type combina-
tions involving the esophagus-pancreas, bladder-thyroid,
brain-stomach and brain-pancreas are genetically related,
but not other combinations reported in Table 1 of our
analysis using BCCR data.
The relatedness of cancer types in this analysis might be
the result of chance, but the large number of observations
contributing to the analysis makes this unlikely. The abso-
lute number of people with some pair of cancer diagnoses
is not indicative of the relatedness of those cancers,
because the probability of developing any pair of cancers
depends on the probability of developing each cancer
independently. A relatedness of cancer types must be
based on their co-occurrence in excess of expectation. The
expected number of people that are diagnosed with a pair
of cancers is determined by the probability that each can-
cer is diagnosed individually. In general, the risk of a can-
cer depends on its incidence in the whole population –
and not on the incidence in only people who have had
two or more types of cancer. We calculated only the prob-
Table 1: Combinations of cancer types with two times or more observed cases than expected.
Pair of Cancer Types Diagnosis of Both Cancers O/E Ratio and 95%CI
Observed (O) Expected (E)
Women
Hodgkin Disease – Ovary 2 0.67 3.0 (0.6, 5.4)
Myeloma – Oral 2 0.69 2.9 (0.5, 5.3)
Bladder – Brain 2 0.80 2.5 (0.3, 4.7)
Esophagus – Melanoma 3 1.26 2.4 (0.7, 4.1)
Cervix – Oral 7 3.05 2.3 (1.2, 3.4)
Leukemia – Pancreas 5 2.30 2.2 (0.9, 3.5)
Brain – Oral 2 0.94 2.1 (0.1, 4.1)
Esophagus – Leukemia 2 0.95 2.1 (0.1, 4.1)
Larynx – Ovary 4 1.93 2.1 (0.7, 3.5)
Kidney – Oral 7 3.46 2.0 (0.9, 3.1)
Men
Larynx – Leukemia 5 1.02 4.9 (3.0. 6.8)
Esophagus – Pancreas 2 0.44 4.6 (1.6, 7.6)
Bladder – Hodgkin Disease 4 1.03 3.9 (2.0, 5.8)
Bladder – Thyroid 6 2.37 2.5 (1.2, 3.8)
Kidney – Larynx 14 5.70 2.5 (1.7, 3.3)
Brain – Pancreas 2 0.87 2.3 (0.2, 4.4)
Larynx – Melanoma 14 6.55 2.1 (1.3, 2.9)
Kidney – Oral 29 13.90 2.1 (1.6, 2.6)
Esophagus – Melanoma 8 3.85 2.1 (1.1, 3.1)
Brain – Stomach 3 1.45 2.1 (0.5, 3.7)
Brain – Larynx 3 1.47 2.0 (0.4, 3.6)Emerging Themes in Epidemiology 2006, 3:17 http://www.ete-online.com/content/3/1/17
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ability of diagnoses in people with more than one primary
cancer, and the O/E value is a measure of the excess occur-
rence of two specific cancer types in people who have
been diagnosed with multiple primary cancers.
Each of the cancer sites paired with melanoma in our
analysis is distinct from the sites paired with melanoma in
previous reports. Our results do not contradict earlier
findings because the methods and assumptions that we
use are different. In our example about cancers related to
melanoma, current CGMIM results (website accessed Sept
5, 2006) indicate there are 16 genes that are related to
both melanoma and bladder cancer. The same results
indicate the gene ZNF202 is related to melanoma and can-
cers affecting the breast, cervix, ovary and lung. Recent
reviews [22,23] suggests that several non-genetic risk fac-
tors that are associated with melanoma risk are also
related to another type of cancer. For instance, occupa-
tional exposure to coal tar and pitches are risk factors for
skin, lung and bladder cancer. Unlike previous analyses,
we do not distinguish the order in which pairs of associ-
ated cancers occurred because there is no reason to
assume the order isn't random. We also believe that some-
one's total number of diagnoses is likely to partly reflect
sporadic events and not reflect the association between
cancer types. An analysis that considers the order or total
number of cancer diagnoses in someone might be useful,
but the consequent reduction in analyzable observations
would substantially limit the findings.
There are limitations that can affect the results from our
method. It is possible that a type of cancer might go undi-
agnosed in some people, however cancer has serious
health effects and undiagnosed cancer does not seem
likely. Not all cancer diagnoses of BC residents might be
recorded by the BCCR because of immigration or emigra-
tion, but we think that the likelihood of someone chang-
ing residences following a cancer diagnosis is small,
particularly if it involves a change in healthcare. Health-
care services in BC are provided free to all residents. It is
also possible that the method's results are affected by ana-
tomic site definitions and cancer recording practices by
the BCCR. However, the "expected" values in our method
are calculated using "observed" totals, so the ratio of
observed and expected values shouldn't be affected much.
Earlier suggestions for analyzing records from people with
multiple cancer diagnoses have included: (1) eliminating
diagnoses that are made within six months following an
earlier diagnosis, (2) excluding diagnoses involving the
same site or affected cell type, and (3) distinguishing cases
by the time interval between diagnoses [24]. Those meth-
ods are intended to allow researchers to better interpret
the results, but researchers should be careful not to be
misled. Our analyses did not include cases of primary can-
cer that were diagnosed at the site of a previous invasive
cancer, nor did we consider the time interval between can-
cer diagnoses. Our motivation was to distinguish cancer
diagnoses that were unlikely to involve metastatic disease
or a recurrence of the initial cancer. While new techniques
improve the ability to distinguish recurrent and metastatic
disease, the historical aspect of the data does not guaran-
tee this problem did not occur in the past. Diagnoses that
occur within six months may suggest that one cancer was
detected because of clinical "work-up" resulting from the
first diagnosis, but the cancers might be related by a
shared factor. Likewise, two diagnoses involving the same
cell type might indicate one cancer is the spread (i.e.,
metastasis) of another, but both cancers might be inde-
pendent and yet etiologically related. Finally, the time
between diagnoses of two cancers in someone might indi-
cate whether the cancers are due to treatment, but it might
also reflect the cancers' natural histories or the ages when
they are most likely to present.
The etiology of most cancers is not fully understood, and
the proposed method is meant to generate insight and
new hypotheses. Additional criteria must be used to estab-
lish whether an etiologic factor affects two or more cancer
types. Determining the relatedness of cancers might lead
to new therapies because a treatment that is effective for
one disease could be as effective for another. The related-
ness of cancers is also important for providing targeted
disease surveillance in all people who have diagnosed
with cancer. Finally, the identification of related cancers is
hoped to suggest a causal agent for some type of cancer
because that same agent is known to affect the risk of a
related type.
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